Home > > Asia And Global Pharmaceutical Contract Development and Manufacturing Market- Size, Share, Growth Rate, and Forecast
The Asia Pharmaceutical Contract Development and Manufacturing market was valued at $26,115.4 Million in 2023, and is projected to reach $53,423.7 Million by 2030 growing at a CAGR of 10.86% from 2024 to 2030. Pharmaceutical Manufacturing Services segment is expected to be the highest contributor to this market, with $21,774.7 Million in 2023, and is anticipated to reach $44,142.9 by 2030, registering a CAGR of 10.72%. Drug Development Services segment is anticipated to reach $4,455.7 Million by 2030 with the highest CAGR of 12.94%. Pharmaceutical Manufacturing Services and Biologics Manufacturing Services segments collectively expected to account for about 92.7% share of the Asia Pharmaceutical Contract Development and Manufacturing market in 2023, with the former constituting around 83.4% share. Drug Development Services and Pharmaceutical Manufacturing Services segments are expected to witness significant growth rates at a CAGR of 12.94% and 10.72% respectively, during the forecast period. Presently, share of these two segments is estimated to be around 90.7% in the overall Asia Pharmaceutical Contract Development and Manufacturing market in 2023, and is anticipated to reach 91.0% by 2030. Service Pharmaceutical Manufacturing Services Biologics Manufacturing Services Drug Development Services End User Big Pharma Small & Mid-size Pharma Generic Pharmaceutical Companies Other End Users BY REGION North America US Canada Europe Germany France UK Italy Spain RoE Asia China Japan India RoAPAC Middle East & Africa Latin America MEA